SCHEMBL13889014

SCHEMBL13889014

Cc1cccc(C)c1OCC(C)NS(=O)(=O)c1ccc2ccccc2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 2/20 0.62
HTR2A P28223 4/20 0.47
HTR2C P28335 4/20 0.47
HTR7 P34969 4/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
SLC1A3 P43003 1/20 0.45
SLC1A2 P43004 1/20 0.45
SLC1A1 P43005 1/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
PKM P14618 1/20 0.45
PKLR P30613 1/20 0.45
KAT6A Q92794 2/20 0.44
HSD11B1 P28845 1/20 0.44
CYP19A1 P11511 1/20 0.44
MAPT P10636 1/20 0.44
HTT P42858 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
F2 P00734 1/20 0.43
LARS1 Q9P2J5 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4524659 0.83 NR3C1 (0.62) NR3C1
SCHEMBL4509097 0.83 NR3C1 (0.59) NR3C1HTTSMN1; SMN2
SCHEMBL4506870 0.82 NR3C1 (0.62) NR3C1HTR7SLC1A3SLC1A2SLC1A1
SCHEMBL13889015 0.82 NR3C1 (0.62) NR3C1SLC1A3SLC1A2SLC1A1SMN1; SMN2
SCHEMBL4515277 0.81 NR3C1 (0.63) NR3C1HTR2ASMN1; SMN2
SCHEMBL4521826 0.80 NR3C1 (0.59) NR3C1L3MBTL1MEN1KMT2ACYP19A1
SCHEMBL4511681 0.80 NR3C1 (0.58) NR3C1PKMKAT6AHTTSMN1; SMN2
SCHEMBL4517748 0.79 NR3C1 (0.61) NR3C1L3MBTL1HTTSMN1; SMN2
SCHEMBL4518136 0.79 NR3C1 (0.64) NR3C1HTR2ASLC1A2MAPT
SCHEMBL4518778 0.79 NR3C1 (0.57) NR3C1HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2009-04-09 US disclosed
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2009-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases NR3C1, NR3C2, NR5A1 NR3C1 1/4885HTR2A 2151/4885HTR2C 2147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.